Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprozinol SCHEMBL317704 | 0.99 | HTR1A (0.58) | HTR1AGAASLC6A4SLC6A3 | |
| Eprozinol SCHEMBL6235398 | 0.99 | HTR1A (0.58) | HTR1AGAASLC6A4SLC6A3 | |
| Eprozinol SCHEMBL1649758 | 0.97 | HTR1A (0.57) | HTR1AGAASLC6A4SLC6A3 | |
| SCHEMBL17771711 | 0.82 | GAA (0.61) | GAASLC6A3 | |
| SCHEMBL7428354 | 0.81 | GAA (0.73) | HTR1AGAASLC6A4SLC6A3 | |
| Zipeprol SCHEMBL364352 | 0.79 | GAA (0.47) | GAA | |
| SCHEMBL17771721 | 0.79 | ALDH1A1 (0.49) | GAA | |
| Zipeprol SCHEMBL5563283 | 0.78 | GAA (0.46) | GAA | |
| Zipeprol SCHEMBL363879 | 0.78 | GAA (0.46) | GAA | |
| SCHEMBL17771722 | 0.77 | HIF1A (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124835-B2 | Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers | Transgenion—International Institute for Regenerative Translational Medicine GmbH (AT) | 2021-09-21 | — | — | US | claimed |
| EP-3152330-B1 | METHODS OF DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING NOVEL MOLECULAR BIOMARKERS | TRANSGENION INT INSTITUTE FOR REGENERATIVE TRANSLATIONAL MEDICINE GMBH (AT) | 2021-01-27 | — | — | EP | claimed |
| US-10604806-B2 | Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers | Transgenion—International Institute for Regenerative Translational Medicine GmbH (AT) | 2020-03-31 | — | — | US | claimed |
| US-20170349947-A1 | METHODS OF DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING NOVEL MOLECULAR BIOMARKERS | TRANSGENION - INTERNATIONAL INSTITUTE FOR REGENERATIVE TRANSLATIONAL MEDICINE GMBH (AT) | 2017-12-07 | — | — | US | claimed |
| US-20170335393-A1 | METHODS OF DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING NOVEL MOLECULAR BIOMARKERS | TRANSGENION - INTERNATIONAL INSTITUTE FOR REGENERATIVE TRANSLATIONAL MEDICINE GMBH (AT) | 2017-11-23 | — | — | US | claimed |
| US-20170107574-A1 | METHODS OF DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING NOVEL MOLECULAR BIOMARKERS | TRANSGENION - INTERNATIONAL INSTITUTE FOR REGENERATIVE TRANSLATIONAL MEDICINE GMBH (AT) | 2017-04-20 | — | — | US | claimed |
| EP-3152328-A2 | METHODS OF DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING NOVEL MOLECULAR BIOMARKERS | TRANSGENION-INTERNATIONAL INSTITUTE FOR REGENERATIVE TRANSLATIONAL MEDICINE GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| EP-3152330-A1 | METHODS OF DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING NOVEL MOLECULAR BIOMARKERS | TRANSGENION-INTERNATIONAL INSTITUTE FOR REGENERATIVE TRANSLATIONAL MEDICINE GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| EP-3152329-A2 | METHODS OF DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING NOVEL MOLECULAR BIOMARKERS | TRANSREGION-INTERNATIONAL INSTITUTE FOR TRANSLATIONAL MEDICINE GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| WO-2015185658-A2 | METHODS OF DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING NOVEL MOLECULAR BIOMARKERS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2015-12-10 | — | — | WO | claimed |
| US-20010006962-A1 | FATTY ACID DERIVATIVES | NORSK HYDRO ASA (NO) | 2001-07-05 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0977725-A1 | NEW FATTY ACID DERIVATIVES | NORSK HYDRO ASA (NO) | 2000-02-09 | — | — | EP | claimed |
| WO-1998032718-A1 | NEW FATTY ACID DERIVATIVES | NORSK HYDRO ASA (NO) | 1998-07-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006962-A1 | FATTY ACID DERIVATIVES | HADH, NR1H2, NR1H3 | HTR1A 1196/4885GAA 3658/4885SLC6A4 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.